Name: HALOZYME THERAPEUTICS INC (HALO) Stock
Brand: HALOZYME THERAPEUTICS INC
Rating: 5 (3 reviews)

HALO Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors

20 days ago - By: Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Bullish Technical Setup

2 days ago - By: Zacks Investment Research

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

5 days ago - By: The Motley Fool

The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.

7 days ago - By: Halozyme Therapeutics, Inc.

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

8 days ago - By: Zacks Investment Research - Mentions: APLS

Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?

10 days ago - By: Zacks Investment Research

What Makes Halozyme Therapeutics (HALO) a New Buy Stock

10 days ago - By: Zacks Investment Research

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

14 days ago - By: Zacks Investment Research

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

16 days ago - By: Halozyme Therapeutics, Inc.

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

23 days ago - By: Halozyme Therapeutics, Inc.

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

24 days ago - By: The Motley Fool - Mentions: RKLB MELI SPSC WING ...

Why I Keep Buying These 10 Incredible Growth Stocks

a month ago - By: Zacks Investment Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

a month ago - By: Investor's Business Daily - Mentions: GMAB

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead?

a month ago - By: Zacks Investment Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

a month ago - By: Halozyme Therapeutics, Inc.

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

a month ago - By: Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

a month ago - By: Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

a month ago - By: Zacks Investment Research - Mentions: JNJ ARGX

Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View

a month ago - By: Zacks Investment Research

Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

a month ago - By: Zacks Investment Research - Mentions: BHST

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

a month ago - By: Halozyme Therapeutics, Inc.

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

a month ago - By: Benzinga - Mentions: ON TIMB GT IRMD ...

Earnings Scheduled For November 3, 2025

a month ago - By: Benzinga

Insights into Halozyme Therapeutics's Upcoming Earnings

2 months ago - By: Zacks Investment Research - Mentions: JNJ

Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?

2 months ago - By: Halozyme Therapeutics, Inc.

Halozyme to Report Third Quarter 2025 Financial and Operating Results

2 months ago - By: Zacks Investment Research

HALOZYME THERAPEUTICS INC (HALO) Stock News

HALO Latest News, Press Relases and Analysis

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Bullish Technical Setup

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?

What Makes Halozyme Therapeutics (HALO) a New Buy Stock

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Why I Keep Buying These 10 Incredible Growth Stocks

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View

Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Earnings Scheduled For November 3, 2025

Insights into Halozyme Therapeutics's Upcoming Earnings

Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?